An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients
NCT ID: NCT01725646
Last Updated: 2014-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
253 participants
INTERVENTIONAL
2011-07-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Evaluation of the safety of Omacor® in Taiwanese hypertriglyceridemia patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus
NCT00328536
Safety Study of BMS-844421 for Treatment of Hypercholesterolemia
NCT01082562
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
NCT06925100
Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia
NCT01211847
A Study to Evaluate COR-1004 in Adult Volunteers.
NCT07229118
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omacor® 4 g
Subjects in this group will take 4 g of Omacor® everyday.
Omacor®
Subjects in 4 g and 2 g Omacor® will take this drug
Omacor® 2 g
Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
Omacor®
Subjects in 4 g and 2 g Omacor® will take this drug
Placebo
Subjects in this group will take 4 g of placebo everyday.
Placebo
Subjects in placebo group will take this drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omacor®
Subjects in 4 g and 2 g Omacor® will take this drug
Placebo
Subjects in placebo group will take this drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient had history of a severe cardiovascular event or a revascularization procedure within 6 months prior to randomization
20 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Excelsior
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chuen-Den Tseng, M.D., PhD.
Role: PRINCIPAL_INVESTIGATOR
NTUH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan
National Cheng Kung University Hospital
Tainan City, Taiwan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OM3-99001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.